Weight gain was reportedly low and similar across all three treatment groups, whereas the rates of confirmed symptomatic hypoglycaemia were 12.2, 12.9 and 17.1 events/person-year in the insulin glulisine once-, twice- and three-times-daily groups, respectively. This evidence concerns the gene INS and Hypoglycemia.